Crucell corporate brochure (PDF)

More documents

Recommendations

Info

70 Crucell’s commitment to the world – Taking responsibility Appendix Performance overview What we said (2009 target setting) What we did (2010 actions) Where we are (2010 outcomes) Where we are going (2010 target setting) KPI: Prevention of illness and deaths Continuous improvement Report annually Number of pipeline products 1 PSCI – Pharmaceutical Supply Chain Initiative. 2 GRI – Global Reporting Initiative. 3 DJSI – Dow Jones Sustainability Indexes. www.crucell.com Maintained similar levels of prevention compared with 2009 Report annually Expanded and advanced our pipeline of investigational vaccines and antibodies Animal welfare Continuous improvement 3Rs (Reduce, Refine, Replace) R&D expenses Continued to apply 3R principles to animal testing for preclinical R&D Report annually Reported in press release (2010 financial results, February 7, 2011) and in this CSR report CSR information management improvement In 2010 roll out Reporting Manual In 2010 report with 100% company coverage In 2011 set action plans (quantitative targets) Responsible supply chain In 2010 incorporate PSCI 1 principles into procurement policy In 2011 train all relevant employees In 2011 100% supplier coverage & monitoring Transparency objectives GRI 2 A+ level CSR reporting in 2015 Remain in DJSI 3 In 2010 improve CSR web page Developed, finetuned and rolled out Reporting Manual Collected and analyzed company-wide data Produced Supplier Code of Conduct based on PSCI principles and incorporating Crucell-specific CSR ambitions and guidelines Created vendor assessment questionnaire to survey key suppliers Devised strategy and program for Crucell ‘supplier days’ (CSR workshops) Made substantial further progress with CSR reporting and performance, as measured by a range of external benchmarks (DJSI, CDP 4 , GRI and Dutch ‘Transparency Benchmark’ 5 ) Improved CSR page on Crucell website 4 CDP – Carbon Disclosure Project. 5 Transparantiebenchmark (Transparency Benchmark), an index published by the Dutch Ministry of Economic Affairs, Innovation and Agriculture. Prevented more than 3.6 million cases of infectious disease and 809,823 deaths Crucell has 12 candidate products in its R&D pipeline Essential safety studies are conducted to minimal extent required by law and in accordance with highest international standards Annual R&D expenses €100 mln in 2010 versus €70.2 mln in 2009 A system for consistent and comprehensive reporting is in place Data coverage is 100% Areas where further training or reporting incentives are needed have been identified Strategy and tools are in place to engage key suppliers in constructive dialogue about Crucell’s CSR guidelines and ambitions Self-declared GRI level C; DJSI listing for second successive year; ‘Transparency Benchmark’ score 96/200 Web page outlines Crucell’s CSR ambition and strategy, and provides links for more information/contact Quantitative Qualitative Continuous improvement Report annually Report annually Continuous improvement 3Rs Report annually 2011: Set action plans and set quantitative targets for environment, health and safety (EHS) indicators In 2011: train all relevant employees in responsible supply chain management In 2011: 80% of top 100 vendors to sign Supplier Code of Conduct (CSR declaration) and take part in CSR assessment Beyond 2011: full coverage & monitoring of supplier target group Hold supplier day with focus on CSR in three countries in 2011 2011: Further improve CSR web page and continue to develop reporting practices 2015: GRI A rating
Crucell’s commitment to the world – Taking responsibility – Appendix People overview What we said (2009 target setting) What we did (2010 actions) Where we are (2010 outcomes) Where we are going (2010 target setting) Number of employees by gender Formulate target in 2010 Achieved 100% data coverage and formulated target Average age of employees Report annually Achieved 100% data collection and formulated target Number of women in management Formulate target in 2010 Achieved 100% data collection and formulated target Number of nationalities Formulate target in 2010 Achieved 100% data collection and formulated target Total number of accidents Formulate target in 2010 Defined reporting criteria, achieved 100% data collection and formulated target Employee turnover Formulate target in 2010 Achieved 100% data collection, refined KPI definition and formulated target Strong and successful recruitment drive Learning & development (L&D) identified by global Human Resources department as key CSR priority; global L&D manager appointed and multiple L&D initiatives launched Percentage of employees receiving regular performance reviews Formulate target in 2010 Achieved 100% data collection and formulated target Added two new KPIs to initial set: Number of own recruits* Absenteeism* 1 Excluding 31 insourced staff in China. 2 US Occupational Safety and Health Administration (OSHA) definition. Quantitative Qualitative Total workforce 1,398 1 (12% increase from 2009); ~47% women Average age 40 years Report annually 84 women in senior management positions, 45% increase versus 2009 Teams show high cultural diversity, particularly in the Netherlands and Switzerland Continue focus on equal-opportunity human resource management worldwide Fair and equitable representation Focus on cross-cultural teams Lost time case (LTC) rate 2 of 0.40 2011: LTC rate of 0.4 or less 2015: LTC rate below 0.2 Voluntary turnover in 2010 was 12.93% Voluntary turnover rate no more than 10% of workforce, excluding temporary staff ~95% > 95% 250 new employees in 2010 were recruited by referral Wide variation in data across sites, suggesting need to sharpen definition of this new KPI Report annually Set criteria in 2011 Report annually 71
Page 1 and 2:
Bringing innovation to global healt
Page 3 and 4:
2010 key highlights Revenues and ot
Page 5 and 6:
Overview - Crucell at a glance Cruc
Page 7 and 8:
Overview - Crucell at a glance broa
Page 9 and 10:
Overview - Crucell: A global perspe
Page 11 and 12:
Overview - Message from our CEO and
Page 13 and 14:
Our business - Research and develop
Page 15 and 16:
Page 17 and 18:
Page 19 and 20:
Page 21 and 22: Our business - Research and develop
Page 23 and 24: Our business - Technologies Crucell
Page 25 and 26: Our business - Technologies PER.C6
Page 27 and 28: Our business - Technologies MAbstra
Page 29 and 30: Our business - Products Crucell foc
Page 31 and 32: Our business - Products Cases of di
Page 33 and 34: Our business - Products areas as we
Page 35 and 36: Crucell’s commitment to the world
Page 71: Crucell’s commitment to the world
Page 77: Crucell’s commitment to the world
Page 80: www.crucell.com Newtonweg 1 2333 CP
show all

Crucell corporate brochure (PDF)

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?